Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

(2017) Georg Karpel-Massler et al.   Expert Opinion on Drug Discovery

Immunotherapy for Prostate Cancer: Where We Are Headed

(2017) Giuseppe Schepisi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface

(2016) Erik R. Nelson et al.   Oncotarget

Imaging Cellular Distribution of Bcl Inhibitors Using Small Molecule Drug Conjugates

(2014) Randy J. Giedt et al.   BIOCONJUGATE CHEMISTRY

ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin

(2014) A. Antignani et al.   MOLECULAR CANCER THERAPEUTICS

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

(2014) Karim Tazi et al.   Cancer Medicine

High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer

(2013) Nicholas C. Hsu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

(2013) V. Chandramohan et al.   CLINICAL CANCER RESEARCH

Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells

(2013) Kevin Hollevoet et al.   JOURNAL OF IMMUNOTHERAPY

YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context

(2013) E. P. Jane et al.   MOLECULAR CANCER THERAPEUTICS

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

(2012) Abid R. Mattoo et al.   INTERNATIONAL JOURNAL OF CANCER

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

(2011) Agnete Svendsen et al.   ACTA NEUROPATHOLOGICA

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma

(2011) Karianne Risberg et al.   PLoS One

Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood

(2010) M. Vogler et al.   CLINICAL CANCER RESEARCH

Ral activation promotes melanomagenesis

(2010) P A Zipfel et al.   ONCOGENE

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling

(2008) M Chekenya et al.   ONCOGENE

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE